PMID- 33197684
OWN - NLM
STAT- MEDLINE
DCOM- 20210621
LR  - 20220531
IS  - 1872-8332 (Electronic)
IS  - 0169-5002 (Linking)
VI  - 150
DP  - 2020 Dec
TI  - Homozygous deletion of CDKN2A in malignant mesothelioma: Diagnostic utility, 
      patient characteristics and survival in a UK mesothelioma centre.
PG  - 195-200
LID - S0169-5002(20)30673-5 [pii]
LID - 10.1016/j.lungcan.2020.10.020 [doi]
AB  - BACKGROUND: Detection of homozygous deletion of the p16 gene (CDKN2A) by 
      fluorescence in situ hybridization (FISH) has been investigated as an ancillary 
      technique in the diagnosis of malignant mesothelioma. METHOD: This retrospective 
      study reviewed the results of all p16 FISH tests performed at a regional 
      mesothelioma centre from February 2012 to November 2019 in cases of possible 
      mesothelioma to examine the diagnostic utility of this test as well as patients 
      characteristics and survival in p16 FISH positive mesothelioma versus p16 FISH 
      negative mesothelioma. RESULTS: P16 FISH testing was requested in 216 
      pathological samples in the study period. The test failure rate was 4% (10/216). 
      Median time from request to result was 10 days (IQR 7-13, range 1-30). The 
      sensitivity, specificity, NPV and PPV were 60 %, 100 %, 39 % and 100 % 
      respectively. There were no false positive results and this genetic aberration 
      was only detected in cases of mesothelioma. The prevalence of p16 FISH positive 
      mesothelioma was higher in cytological specimens compared to histological 
      specimens (75 % vs 58 %, p = 0.03) and lower in women compared to men (33 % vs 66 
      %, p = 0.003). P16 FISH positive mesothelioma was associated with significantly 
      worse survival (median overall survival 285 vs 339 days, p = 0.0018). This 
      remained significant after adjusting for confounding variables (OR 4.4, 95 %CI 
      1.84-11.14, p = 0.001). CONCLUSIONS: In this study, 60 % of mesotheliomas harbour 
      a homozygous deletion of CDKN2A and can be accurately, reliably and efficiently 
      identified by p16 FISH testing. This test can be embedded within routine practice 
      in mesothelioma pathways to enhance diagnostic accuracy.
CI  - Copyright (c) 2020. Published by Elsevier B.V.
FAU - Marshall, Kelly
AU  - Marshall K
AD  - Pleural Medicine, North West Lung Centre, Wythenshawe Hospital, Manchester 
      University NHS Foundation Trust, Manchester, UK.
FAU - Jackson, Susan
AU  - Jackson S
AD  - Pleural Medicine, North West Lung Centre, Wythenshawe Hospital, Manchester 
      University NHS Foundation Trust, Manchester, UK.
FAU - Jones, Jennifer
AU  - Jones J
AD  - Pleural Medicine, North West Lung Centre, Wythenshawe Hospital, Manchester 
      University NHS Foundation Trust, Manchester, UK.
FAU - Holme, Jayne
AU  - Holme J
AD  - Pleural Medicine, North West Lung Centre, Wythenshawe Hospital, Manchester 
      University NHS Foundation Trust, Manchester, UK.
FAU - Lyons, Judith
AU  - Lyons J
AD  - Pleural Medicine, North West Lung Centre, Wythenshawe Hospital, Manchester 
      University NHS Foundation Trust, Manchester, UK.
FAU - Barrett, Emma
AU  - Barrett E
AD  - Department of Medical Statistics, Wythenshawe Hospital, Manchester University NHS 
      Foundation Trust, Manchester, UK.
FAU - Taylor, Paul
AU  - Taylor P
AD  - Department of Medical Oncology, North West Lung Centre, Wythenshawe Hospital, 
      Manchester University NHS Foundation Trust, Manchester, UK.
FAU - Bishop, Paul
AU  - Bishop P
AD  - Department of Cellular Pathology, Wythenshawe Hospital, Manchester University NHS 
      Foundation Trust, Manchester, UK.
FAU - Hodgson, Clare
AU  - Hodgson C
AD  - Department of Cytogenetics, The Christie NHS Foundation Trust, Wilmslow Rd, 
      Manchester M20 4BX, UK.
FAU - Green, Michael
AU  - Green M
AD  - Department of Cytogenetics, The Christie NHS Foundation Trust, Wilmslow Rd, 
      Manchester M20 4BX, UK.
FAU - Telford, Nicholas
AU  - Telford N
AD  - Department of Cytogenetics, The Christie NHS Foundation Trust, Wilmslow Rd, 
      Manchester M20 4BX, UK.
FAU - Evison, Matthew
AU  - Evison M
AD  - Pleural Medicine, North West Lung Centre, Wythenshawe Hospital, Manchester 
      University NHS Foundation Trust, Manchester, UK. Electronic address: 
      m.evison@nhs.net.
LA  - eng
PT  - Journal Article
DEP - 20201105
PL  - Ireland
TA  - Lung Cancer
JT  - Lung cancer (Amsterdam, Netherlands)
JID - 8800805
RN  - 0 (CDKN2A protein, human)
RN  - 0 (Cyclin-Dependent Kinase Inhibitor p16)
SB  - IM
MH  - *Cyclin-Dependent Kinase Inhibitor p16/genetics
MH  - Female
MH  - Genes, p16
MH  - Homozygote
MH  - Humans
MH  - In Situ Hybridization, Fluorescence
MH  - *Lung Neoplasms/diagnosis/genetics
MH  - Male
MH  - *Mesothelioma/diagnosis/genetics
MH  - *Mesothelioma, Malignant
MH  - Retrospective Studies
MH  - Sequence Deletion
MH  - United Kingdom
OTO - NOTNLM
OT  - CDKN2A
OT  - Mesothelioma
OT  - p16 FISH
EDAT- 2020/11/17 06:00
MHDA- 2021/06/22 06:00
CRDT- 2020/11/16 20:10
PHST- 2020/09/16 00:00 [received]
PHST- 2020/10/22 00:00 [revised]
PHST- 2020/10/27 00:00 [accepted]
PHST- 2020/11/17 06:00 [pubmed]
PHST- 2021/06/22 06:00 [medline]
PHST- 2020/11/16 20:10 [entrez]
AID - S0169-5002(20)30673-5 [pii]
AID - 10.1016/j.lungcan.2020.10.020 [doi]
PST - ppublish
SO  - Lung Cancer. 2020 Dec;150:195-200. doi: 10.1016/j.lungcan.2020.10.020. Epub 2020 
      Nov 5.